Tg(CAG-cre/Esr1*)5Amc
Transgene Detail

Summary

• Symbol: Tg(CAG-cre/Esr1*)5Amc
• Name: transgene insertion 5, Andrew P McMahon
• MGI ID: MGI:2182767
• Synonyms: CAG-CreEr, CAGG-Cre, CaggCreER, CAGGCre-ER, CAGGCre-ER^TM, CAGGCre-ERtm line 5.8, CAGGS-CreER, CAGGS-CreErT, CMV-creERT, Cre-ER, Cre-ER^TM, CreESR^T, ER-cre, Tg:Cag-Cre/Esr1, Tg(CAG-cre/Esr1)5Amc, TgCAGGCreER, Tg^CreER, Tg(cre/Esr1)5Amc, uCreER^T
• Transgene: Tg(CAG-cre/Esr1*)5Amc Location: unknown
• Alliance: Tg(CAG-cre/Esr1*)5Amc page

Transgene origin

• Strain of Origin: (C57BL/6 x CBA)F1

Transgene description

• Transgene Type: Transgenic (Inducible, Recombinase)
• Inducer: tamoxifen
• Mutation: Insertion
• Tg(CAG-cre/Esr1*)5Amc expression driven by 1 gene
  Transgene expression driven by:
  

  Organism	Driver Gene	Note
  chicken	CAG

• Mutation details: This transgene expresses a fusion protein consisting of Cre recombinase joined to the ligand-binding domain of a mouse estrogen receptor modified to bind to 4-hydroxytamoxifen, but not to endogenous estrogen. The CAG promoter, containing a chicken beta actin promoter/enhancer coupled with the cytomegalovirus immediate-early (CMV-IE) enhancer, drives high levels of expression in most tissues. In the presence of tamoxifen, the fusion protein is transported into the nucleus, where cre can excise loxP-flanked segments from conditionally modified genes. (J:76130)

Recombinase activity

Activity:	Tissue activity of this recombinase allele
Driver:	CAG (chicken) Summary of all recombinase alleles driven by CAG.
User Notes:	Additional information submitted by the research community Additional information submitted by the research community Adult induction of heterozygous status can serve as a proxy for pharmacological inhibition of molecular targets in the absence of pharmacological inhibitors, and as a genetic confirmation of target engagement. To induce heterozygous status in mice at a defined age requires a global inducible promoter that is not leaky, and achieves full recombination upon induction. We evaluated heterozygous deletion of Gls1 in the brains of CAGGCre-ERTM;GLS1lox/+ mice (bred from RRID:IMSR_JAX:004682, RRID:IMSR_JAX:017894), by quantitative genotyping (TransNetyx) to assess Gls1 allelic abundance. Allelic abundance was evaluated in four brain regions (cerebellum, cortex, hippocampus, striatum), and then combined to give an All Regions result. Experiment 1In the absence of induction (4OH-tamoxifen, Afimoxifene), there was a progressive leakiness that was already evident at 2 weeks of age, and extended to 6 months of age. Experiment 2 Induction with Afimoxifene at 2 months of age produced near complete recombination, with daily treatment for 3 days, and no additional recombination with treatment for 5 days. There was no significant variation amongst the brain regions. Although the CAGGCre-ERTM driver achieves brain-wide recombination, progressive leakiness limits its utility for adult induction of heterozygous status. Pers. Comm. Dr. Stephen Rayport March 2025

Disease models

Expression

In Structures Affected by this Mutation:

2 anatomical structure(s)

Tumor Data

List all tumor models in MMHCdb carrying Tg(CAG-cre/Esr1*)5Amc

Find Mice (IMSR)

• Mouse strains and cell lines available from the International Mouse Strain Resource (IMSR)
• Carrying this Mutation: Mouse Strains: 10 strains available Cell Lines: 0 lines available

Notes

Homozygous transgenic mice are not viable or fertile. Hemizygous transgenic mice are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities.

In transgenic mice the mutant mouse estrogen receptor does not bind natural ligand at physiological concentrations but will bind the synthetic ligand, 4-hydroxytamoxifen. Restricted to the cytoplasm, the Cre/Esr1 fusion protein can only gain access to the nuclear compartment after exposure to tamoxifen. When crossed with a strain containing loxP sites flanking a sequence of interest, tamoxifen induced, Cre-mediated targeted deletions are generated in the offspring. Tamoxifen administration will induce Cre recombination in developing embryos of treated mothers and in cultured cells derived from transgenic mice.

Note that this transgene does not contain the cre/ERT2 fusion but was mistakenly referred to by the synonym CAG-CreERT2 in publication. J:136965

Note that this transgene does not contain the cre/ERT2 fusion but was mistakenly referred to by the synonym CAGG-CreERT2 in publication. J:130851

References

• Original: J:76130 Hayashi S, et al., Efficient recombination in diverse tissues by a tamoxifen-inducible form of cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol. 2002 Apr 15;244(2):305-18
• All: 792 reference(s)